Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estrogen and Probiotics for Vaginal Health in ACB Women
NCT03837015Phase 1Completed
- Sponsor
- McMaster University
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of estradiol and lactobacillus rhamnosus GR-1 + lactobacillus reuteri RC-14 in human immunodeficiency virus infection (HIV) and bacterial vaginosis (BV) (4 arms), sponsored by McMaster University. Primary endpoints: Refusal rate at 12 months, Participant retention rate at 12 months and 2 more. Started Nov 2019; status: completed.
02
Drugs
estradiollactobacillus rhamnosus GR-1 + lactobacillus reuteri RC-14
03
Conditions
human immunodeficiency virus infection (HIV)bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT03837015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837015.